Marvell Technology Group Ltd (MRVL)

Conclusion

Marvell Technology Group is a US semiconductor company that designs data infrastructure chips, from networking and interconnect products for data centres to storage controllers and connectivity products at the network edge. At a price of 154.6 USD on 9 November 2026, the market capitalisation is 135.7 billion USD.

The verdict is overvalued. The fair value band runs from 43.68 to 65.52 USD with a midpoint of 54.60 USD, giving a margin of safety of -64.7% at the current price. Most multiples sit above their own ten-year medians: price to free cash flow is 78.5x against a median of 50.7x, and price to book is 7.3x against 3.1x. Enterprise value to EBITDA, at 28.8x, is close to its median of 28.6x. The DCF gives 17.25 USD per share at a discount rate of 16.5%, while the fair value from historical multiples is 91.96 USD. The growth the price implies in the reverse DCF is not available, because the model returned a value outside its usable range. Over the past five years, revenue compounded at 22.5% and free cash flow per share at 9.0%.

What holds the case up is a strong balance sheet, with an Altman Z-score of 10.10 and net debt to EBITDA of 0.28, a 16.7% operating margin, and five-year revenue growth of 22.5%. What would break it is returns that sit just below the cost of capital, with ROIC at 15.4% against WACC of 16.1%, a likely-manipulation reading from the Beneish M-score of -1.59, and a share count that has risen 5.4% a year over five years.

Financial health

Financial health is green, held up by a current ratio of 3.17, a quick ratio of 2.46, net debt to EBITDA of 0.28, interest coverage of 16.2 and debt to equity of 0.29. The Altman Z-score is 10.10, in the safe zone, although the model was designed for manufacturers, so the reading should be taken with that in mind. Insolvency risk is low, at about 0.06% by the estimate of the Ohlson model over one to two years.

Earnings quality

Earnings quality is red. Free cash flow conversion is 65.5% on a trailing basis, while the five-year figure is 2062.1%, an unusually high number that is hard to interpret on its own. The accrual ratio is 4.3%, and stock-based compensation is 8.8% of revenue, leaving 901.2 million USD of free cash flow after it. The share count has grown 5.4% a year over five years, so there are no net buybacks. The Piotroski score is 7 of 9, while the Beneish M-score of -1.59 is labelled likely manipulation. The company beat estimates in 6 of its last 8 quarters, with one miss and an average surprise of 1.1%. Next-year EPS estimates rose 17.7% over 90 days, with 26 upward revisions and 1 downward in the last 30 days.

Profitability

Profitability is green. The gross margin is 51.4% against a ten-year median of 50.4%, the operating margin is 16.7% against a median of -1.4%, and the net margin is 27.9% against a median of -4.5%. Operating margin stability reads 10.06. ROIC is 15.4% against a WACC of 16.1%, a ROIC minus WACC value of -0.6%, labelled neutral. The five-year median ROIC is -1.5%. Return on equity of 14.3% is not inflated by leverage: the DuPont split shows a net margin of 32.6%, an asset turnover of 0.37 and an equity multiplier of 1.56, as of January 2026. The margin recovery is real, but returns still sit just below the cost of capital.

Growth

Growth is green. Revenue compounded at 11.5% over three years, 22.5% over five years and 12.0% over ten years. Free cash flow per share grew at 8.5%, 9.0% and 18.6% over the same periods. Revenue rose in 7 of 10 comparable years. EPS growth is not available. Analysts expect next-year EPS growth of 73.9%. That is a forecast rather than delivered growth, and it is the main reason the forward view looks stronger than the record.

Valuation

Valuation is red. The price-to-earnings multiple is 51.4x, but there are only four data points, so no ten-year median is available. Enterprise value to EBITDA is 28.8x against a median of 28.6x, a premium of 0.8%. Price to free cash flow is 78.5x against 50.7x, a premium of 54.8%. Price to sales is 14.4x against 7.8x, a premium of 83.9%. Price to book is 7.3x against 3.1x, a premium of 137.0%. The DCF gives 17.25 USD per share, using a 16.5% discount rate, 20.0% stage-one growth and 2.5% terminal growth. The fair value band is 43.68 to 65.52 USD, and the fair value from historical multiples is 91.96 USD. The fair value figures are order-of-magnitude estimates built on fixed assumptions, including a 5% equity risk premium and capped growth, and are not price targets. The reverse DCF implied growth is not available. The dividend yield is 0.15%, with a payout of 12.1% of free cash flow.

Risks

If the ROIC shortfall against WACC persists, the company is not earning its cost of capital, and growth would add less value per share. The likely-manipulation reading from the Beneish M-score calls for scrutiny of reported earnings, and continued dilution of 5.4% a year erodes per-share value. The premiums on price to free cash flow and price to book leave little room if growth slows. The beta of 2.327 means the share price is likely to move sharply in both directions. Several values are not available: the reverse DCF implied growth, EPS growth over three to ten years, and any debt maturity schedule or revenue by segment. Those gaps, together with the Altman model's design for manufacturers and the fixed assumptions behind the DCF, limit how far this analysis can be pushed.